Circulating antiphospholipid antibodies (aPL) are associated with a syndrome of thrombosis, recurrent fetal loss, and thrombocytopenia. We have demonstrated the activation of cultured human umbilical vein endothelial cells (HUVEC) by IgG from patients with anticardiolipin antibodies (aCL).
Introduction
The presence of circulating antiphospholipid antibodies (aPL)1 is associated with a clinical syndrome characterized by venous Azzudin E. Gharavi Received for publication 11 April 1995 and accepted in revised form 8 August 1995. and arterial thrombosis, recurrent fetal loss, thrombocytopenia, and neurologic disease (1) . The thrombotic disease can occur at an early age and can be associated with devastating clinical sequelae. The antiphospholipid antibody syndrome is most often seen in patients with SLE, but also occurs in patients without other evidence of collagen vascular or autoimmune disease (primary antiphospholipid syndrome [PAPS]) (2) . aPL autoantibodies, including lupus anticoagulant and anticardiolipin antibody (aCL), are reactive with negatively charged phospholipids. Reactivity of aCL in vitro depends on the presence of a protein cofactor, i2-glycoprotein 1 (32GP1, apolipoprotein H) (3), a 50-kD plasma protein, which may form a complex with cardiolipins to confer specificity for aCL (4) .
Epidemiologic studies have demonstrated an increase in thrombosis in SLE patients who have measurable aPL, as well as an increase in thrombotic events in patients with aPL and no other underlying disease (5, 6) . In addition, studies of the lupusprone MRL mouse and animals passively immunized with aPL IgG demonstrate aPL-associated thrombosis and spontaneous abortion (7, 8) . Although these represent strong evidence that aPL may be pathogenic, the molecular basis of the prothrombotic phenotype associated with these antibodies is unknown.
Numerous studies have attempted to demonstrate an effect of aPL on fluid phase coagulation enzymes or inhibitors (1) . It is clear that while these antibodies often inhibit plasma thrombin generation in in vitro assays, they are not associated with a clinical anticoagulant effect. While no consistent evidence of interference with antithrombin HI or with the fibrinolytic system has been found, some studies have shown that IgG fractions from patients with SLE may interfere with thrombomodulinmediated protein C activation or with phospholipid-dependent protein C activity (9, 10) . These results have not been shown to correlate with clinical thrombosis.
Most recent attention has therefore focused on the possible interaction of aPL with cellular regulators of hemostasis, especially platelets and endothelial cells. Work in our laboratory and others has failed to demonstrate platelet activation by aPL, although aPL has been shown to bind to previously activated platelets ( 11) . Platelets opsonized by aPL may be cleared more rapidly from the circulation, and may account for the thrombocytopenia associated with aPL syndrome, although it is difficult to explain the clinical hypercoagulability on this basis.
Since the vascular endothelium is a major regulator of hemostasis, it is reasonable to speculate that the hypercoagulable state associated with aPL may be due to interference with normal endothelial cell function. In patients with SLE and aPL there is indirect evidence of endothelial cell activation, including increased circulating levels of von Willebrand factor (12) . Previous studies have also shown that IgG from patients with aPL can bind to endothelial cells ( 13, 14) . However, endothelial cell reactivity has not been shown to correlate with aCL activ-ity or with the clinical manifestations of the aPL syndrome (15, 16) .
In Purification of IgG. IgG from patients or normal subjects was purified as described ( 18) , by protein G-Sepharose 4B affinity chromatography (Zymed Laboratories, Inc.). All IgG preparations were free of contaminating /62GPI as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and were found to have LPS level < 0.06 ng/ml as determined by limulus lysate assay (Ameolysate; ICN Biochemical, Costa Mesa, CA). Anticardiolipin antibody titer was determined by ELISA as previously described (23), using purified IgG at a concentration of 75-100 Mg/ml. The upper limit of linearity of the assay is 80 gamma phospholipid units (GPL), therefore values exceeding this level are reported as "> 80". Some patients' sera were incubated overnight at 40 with cardiolipin liposomes (5 mg/ml), which were prepared as described (24) .
Rabbit polyclonal /2 glycoprotein 1-induced antibodies. Polyclonal rabbit antiserum with both anti-/62GPl and anticardiolipin reactivity was produced by immunization of a New Zealand white rabbit with purified human /62GP1 (25). As previously described, the antibody populations were non-cross-reactive, and the aCL reactivity 632GPI-dependent.
Adhesion assay. HUVEC were seeded onto 0.1% gelatin-coated Terasaki plates (Miles Laboratories Inc., Naperville, IL) at a cell density of 1 x 106 cells/ml, allowed to grow at 370C for 1 d, and then washed once with M199. Cells were incubated with purified human IgG (100 Mg/ml) diluted in serum-containing medium, which has been shown to provide cofactor necessary for aCL binding (18) , and incubated at 370C for 4 h or other time points as specified. In some experiments, HUVEC were incubated for 15 
Results
Induction ofmonocyte adhesion to vascular endothelial cells by IgG from patients with anticardiolipin antibodies. We studied induction of endothelial cell adhesiveness for monocytes as a biological assay to detect the activated phenotype induced by IgG isolated from patients with aPL. We used Mono Mac 6 (MM6) cells, which have been shown to express ligands for endothelial cell adhesion molecules and to behave similarly to isolated human monocytes in adhesion assays with cytokineactivated endothelium (27) . In a series of preliminary studies, IgG were obtained from 10 patients with clearly identifiable clinical events and aCL titers exceeding 80 GPL, and from 10 normal subjects. As seen in Fig. 1 The 4-h time lag required for the development of the adhesive phenotype suggests the synthesis and expression of new adhesion proteins by HUVEC. We therefore performed immunofluorescence microscopy on HUVEC which had been incubated for 4 h with patient IgG, using antibodies to known cell surface adhesion molecules. We found, as shown in Fig. 2 , that endothelial cells incubated with aCL IgG expressed surface Eselectin, VCAM-1, and ICAM-1, while endothelial cells incubated with normal patient IgG expressed only low levels of ICAM-1. We then performed the adhesion assay in the presence of blocking monoclonal antibodies to cell adhesion molecules. Antibody to E-selectin blocked 80% of monocyte adhesion; the combination of all three antibodies blocked all monocyte adhesion to the endothelial cells (P < 0.05) (Fig. 3) . Although the antibody to VCAM-1 is known to have blocking activity (28), it did not block monocyte adhesion to endothelial cells in our system (Fig. 3) . Nonimmune mouse IgG was used as a negative control, and had no effect. These data show that the adhesive phenotype produced by endothelial cell exposure to aCL was due to new expression of specific adhesion receptors.
Specificity of aCL effect on HUVEC. LPS contamination did not account for the effects of aCL on the endothelial cells. All of IgG preparations had undetectable levels of LPS (< 0.06 ng/ml) by limulus lysate assay. Furthermore, incubation of three aCL-positive patient IgGs with polymyxin B-coated agarose to remove any potentially contaminating LPS did not abrogate the adhesion induced by these samples (Fig. 4) .
To exclude the possibility that Fcy receptor interactions accounted for the proadhesive activity of IgG from patients with aCL, we performed adhesion studies in the presence of blocking antibodies. Immunofluorescence and flow cytometric analysis revealed that MM6 expressed FcyRII. Although they did not react with a panel of FcyRI antibodies, the MM6 exhibited low levels of binding to murine IgG2A, suggesting FcyRl activity (Lo, S.K., and J.E. Salmon, unpublished observations). Saturating concentrations of anti-FcyRII monoclonal antibody (IV. 3) or IgG2A (50 ,pg/ml) that block the ligand binding sites of Fc-yRll and FcyRI, respectively, had no effect on adhesion mediated by IgG from three PAPS patients and two SLE patients with aCL (Fig. 4) . Incubation of HUVEC with aggregated IgG (100 Ag/ml) did not lead to monocyte adhesion (331+276 cells/mm2), nor did aggregated IgG affect aCL-induced adhesion (985±171 vs 891±92 cells/mm2). Monocyte adhesion was also not caused by incubation of HUVEC with a combination of rabbit anti-human albumin (100 Ag/ml) with 50-200 Ag/ ml human serum albumin (90±84 cells/mm2), arguing against an immune complex-mediated effect. 16 GPL) , but had no effect on other SLE-related autoantibodies, including ANA and anti-DNA (data not shown). As seen in Fig. 4 , when endothelial cells were incubated with these preadsorbed patient sera, we observed a significant reduction in the level of monocyte adhesion (P < 0.01). This is further evidence for the Purified IgG from patients with SLE and PAPS was assayed for aCL, expressed as GPL and AECA, expressed as a binding index (BI)±standard error, as described in the Methods. Values above 80 GPL, the upper limit of linearity of the assay, are reported as "> 80." Patient IgG were incubated with HUVEC and adhesion of MM6 cells, expressed as cells/mm2, was determined as described in the Methods. Adhesion values are the mean of two to three experiments, each done in triplicate. N.D., not done. * Patient had positive lupus anticoagulant. specific role of aCL, rather than other SLE-related autoantibodies, in activation of endothelial cells.
Furthermore, IgG isolated from a rabbit immunized with purified /32GP1, that was previously shown to react with cardiolipin in a 32GPI-dependent manner (25) , also activated HU-VEC. As seen in Fig. 6 , HUVEC incubated with this IgG acquired the capacity to bind monocytes in a concentration-dependent fashion. In addition, this effect was diminished when the IgG preparation was preadsorbed with f32GP1 (1,230±237 vs 583 ±299 cells/mm2). Normal rabbit IgG did not increase adhesion above control (Fig. 6) , indicating a specific effect of the f2GP1 antibody.
Relationship of endothelial cell activation by aCL to SLE. To determine if the presence of SLE in patients with aCL contributed to these findings, we studied IgG from five patients with primary antiphospholipid syndrome, five patients with antiphospholipid antibody syndrome and concomitant SLE, and eight patients with SLE but no detectable aCL. As shown in Fig. 7 and Table I the eight SLE patients without detectable aCL had a positive lupus anticoagulant (patient 27, Table I ). This did not change the statistical significance of our findings.
Discussion
The vascular endothelium is the major site of preservation of the nonthrombogenic state. This state is maintained by constitutive expression of natural anticoagulant systems, including thrombo- (29, 30) . In this manuscript, we show that the antiphospholipid antibody syndrome, a hypercoagulable state associated with high circulating titers of autoantibodies against anionic phospholipids, may be the result of such endothelial activation by a unique antibody-dependent mechanism. We used induction of endothelial cell adhesiveness for MM6 cells as a biologic assay to detect the activated phenotype induced by IgG purified from patients with aCL. The adhesive phenotype was shown to be the result of induced expression of specific adhesion molecules, including E-selectin, VCAM-1, and ICAM-1. Adhesion was not attributable to contaminating endotoxin, immune complexes, or to Fc receptor interactions, but rather was mediated by the specific anticardiolipin reactivity of the IgG. The endothelial-activating capacity of the IgG's was blocked by adsorption with cardiolipin liposomes, and was dependent on the presence of f2GP1, a protein cofactor previously shown to be necessary for aCL reactivity. Furthermore, rabbit IgG with anticardiolipin reactivity that was raised by immunization with purified ,32GPI also produced a similar activation of cultured endothelial cells.
We showed that IgG's from patients with aCL bind to HU-VEC as determined by enzyme-linked immunoassay, however activation of endothelial cells was not dependent upon the level of endothelial cell reactivity of our IgG preparations. In addition, binding by control antibodies with endothelial cell reactivity was not sufficient to induce activation. As others have pre-viously shown, we found that aPL antibodies were distinct from the AECA described in patients with autoimmune disease (13) (14) (15) (16) . We demonstrated that the effect of aPL in activating endothelial cells was independent of the level of endothelial cell reactivity. AECA (32) .
Thus far, there has been no reliable predictor of thrombotic events in patients with aCL. Recent studies have reported that aPL may interfere with the protein C anticoagulant pathway, inhibiting phospholipid-dependent activated protein C activity (10) . However, not all patients with aPL develop thrombotic complications, and the clinical manifestations of aCL in SLE and non-SLE patients are heterogeneous (1, 6) . It is likely, therefore, that a constellation of activities of antiphospholipid antibodies, including effects on coagulation enzymes and endothelial cells, is necessary to tip the balance toward the clinical phenotype. It is possible that these patients have ongoing endothelial cell activation, and clinically relevant events may occur when the patients are subjected to an additional factor, which then leads to vascular thrombosis or fetal loss in certain settings. It remains to be seen whether the level of endothelial cell activation in vitro correlates with clinical thrombotic events. In our study, the highest level of endothelial cell activation was induced by aCL from patients with PAPS, however further work needs to be done to more accurately predict the risk of thrombosis in patients with aPL.
